Answers are grounded in this paper and cite their sources.
Significance In this work, we describe a dual-action inhibitor that simultaneously disrupts functions of two key MYC-mediating factors—PI3K and BRD4. We show that the concomitant inhibition of PI3K and BRD4 blocks MYC expression and activation, promotes MYC degradation, and markedly inhibits cancer cell growth and metastasis. Our findings suggest that the dual-activity inhibitor represents a highly promising lead compound for the development of novel anticancer therapeutics.
No takes yet. Share an insight, caveat, or question.
Andrews et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: